product

26 articles in this category (Page 2 of 2)

managementearningsproduct

Tesla (TSLA) Faces Mixed Signals Amid Falling Deliveries and High Valuation: Sideways Outlook

Despite analyst upgrades, Tesla's declining deliveries and massive 14% gap between gross and net margins suggest a sideways consolidation phase.

Feb 24, 2026TSLA

regulatoryproductearnings

ImmunityBio (IBRX) 21-Day Outlook: Increase Expected Amidst Global ANKTIVA Approvals Despite Overbought Technicals

ImmunityBio's massive 700% revenue growth and new international ANKTIVA approvals signal upside potential, though overbought technicals and deep negative margins cap confidence.

Feb 23, 2026IBRX